Association of Cardiovascular Disease With Respiratory Disease.

[1]  M. Molina-Molina,et al.  Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction , 2017, The clinical respiratory journal.

[2]  R. Collins,et al.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[3]  A. Boyle,et al.  The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis , 2017, Front. Physiol..

[4]  P. Bundhun,et al.  Major adverse cardiac events and mortality in chronic obstructive pulmonary disease following percutaneous coronary intervention: a systematic review and meta-analysis , 2017, BMC Cardiovascular Disorders.

[5]  W. Tan,et al.  Association of asthma with coronary heart disease: A meta analysis of 11 trials , 2017, PloS one.

[6]  Kunpeng Wang,et al.  Asthma and risk of coronary heart disease: A meta-analysis of cohort studies. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  D. Culliford,et al.  Improved outcomes in ex-smokers with COPD: a UK primary care observational cohort study , 2017, European Respiratory Journal.

[8]  F. Martinez,et al.  Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk , 2017, Heart.

[9]  M. Karsdal,et al.  High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD – results from the ECLIPSE study , 2016, Respiratory Research.

[10]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[11]  S. Chandran,et al.  The impact of psychiatric comorbidities on the length of hospital stay in patients with heart failure. , 2016, International journal of cardiology.

[12]  G. Raghu,et al.  Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review , 2015, European Respiratory Journal.

[13]  S. Chandran,et al.  Risk factors for mortality in Down syndrome. , 2015, Journal of intellectual disability research : JIDR.

[14]  Claudia E Korcarz,et al.  Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[15]  L. Smeeth,et al.  Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease , 2015, Heart.

[16]  N. Ali,et al.  The role of angioplasty in patients with acute coronary syndrome and previous coronary artery bypass grafting. , 2014, International journal of cardiology.

[17]  J. Wedzicha,et al.  Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[18]  G. Pledger,et al.  Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.

[19]  A. Agustí,et al.  Cardiovascular comorbidity in COPD: systematic literature review. , 2013, Chest.

[20]  Benjamin M. Smith,et al.  Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. , 2013, Chest.

[21]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[22]  Florent Baty,et al.  Comorbidities and Burden of COPD: A Population Based Case-Control Study , 2013, PloS one.

[23]  T. Brady,et al.  Arterial inflammation in bronchial asthma , 2013, Journal of Nuclear Cardiology.

[24]  Antonio Colombo,et al.  Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II , 2013, The Lancet.

[25]  A. Høiseth,et al.  High-sensitivity cardiac troponin T levels are increased in stable COPD , 2013, Heart.

[26]  C. Iribarren,et al.  Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. , 2012, American journal of epidemiology.

[27]  B. Nordestgaard,et al.  Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[28]  H. Collard,et al.  Burden of illness in idiopathic pulmonary fibrosis , 2012, Journal of medical economics.

[29]  Sameer Ather,et al.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. , 2012, Journal of the American College of Cardiology.

[30]  P. Enright,et al.  Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.

[31]  J. Vestbo,et al.  Cardiovascular Morbidity in COPD: A Study of the General Population , 2011, COPD.

[32]  Laura C Rodrigues,et al.  Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care , 2010, Thorax.

[33]  T. Holford,et al.  Geographic Variation in One-Year Recurrent Ischemic Stroke Rates for Elderly Medicare Beneficiaries in the USA , 2010, Neuroepidemiology.

[34]  Joseph Finkelstein,et al.  Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity , 2009, International journal of chronic obstructive pulmonary disease.

[35]  A. Valipour,et al.  Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[36]  R. Hubbard,et al.  The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. , 2008, American journal of respiratory and critical care medicine.

[37]  G. Giannakoulas,et al.  Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue Doppler echocardiographic study , 2008, European Respiratory Journal.

[38]  J. Vestbo,et al.  Potential misclassification of causes of death from COPD , 2006, European Respiratory Journal.

[39]  E. Salpeter,et al.  Meta-Analysis: Effect of Long-Acting -Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths , 2006, Annals of Internal Medicine.

[40]  S. Sidney,et al.  COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. , 2005, Chest.

[41]  D. Sin,et al.  The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. , 2005, Chest.

[42]  Deepak L. Bhatt,et al.  Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative , 2004 .

[43]  T. Seemungal,et al.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels , 2000, Thrombosis and Haemostasis.

[44]  Hitoshi Hara,et al.  Airflow limitation in smokers is associated with subclinical atherosclerosis. , 2009, American journal of respiratory and critical care medicine.